drugset / Trial / NCT00382616

Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD

NCT00382616 ↗

Phase 2 Completed 90 enrolled Tel-Aviv Sourasky Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine whether supplementation of omega-3 long-chain polyunsaturated fatty acid conjugated to phosphatidylserine rather than triglycerides (fish oil) could affect Attention-deficit/hyperactivity disorder symptoms in children.

Timeline

Start
2004-07
Primary completion
—
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Phosphatidylserine-Omega3 Other / unclassified 300 mg —